1. Home
  2. RYAN vs STVN Comparison

RYAN vs STVN Comparison

Compare RYAN & STVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Ryan Specialty Holdings Inc.

RYAN

Ryan Specialty Holdings Inc.

HOLD

Current Price

$58.27

Market Cap

7.3B

Sector

Finance

ML Signal

HOLD

Logo Stevanato Group S.p.A.

STVN

Stevanato Group S.p.A.

HOLD

Current Price

$23.05

Market Cap

7.4B

ML Signal

HOLD

Company Overview

Basic Information
Metric
RYAN
STVN
Founded
2010
1949
Country
United States
Italy
Employees
N/A
N/A
Industry
Specialty Insurers
Containers/Packaging
Sector
Finance
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
7.3B
7.4B
IPO Year
2021
2021

Fundamental Metrics

Financial Performance
Metric
RYAN
STVN
Price
$58.27
$23.05
Analyst Decision
Buy
Buy
Analyst Count
14
4
Target Price
$67.50
$25.88
AVG Volume (30 Days)
1.5M
361.2K
Earning Date
10-30-2025
11-06-2025
Dividend Yield
0.83%
0.27%
EPS Growth
N/A
19.61
EPS
N/A
0.60
Revenue
$2,905,944,000.00
$1,373,219,524.00
Revenue This Year
$27.58
$8.33
Revenue Next Year
$16.69
$10.12
P/E Ratio
$217.26
$39.08
Revenue Growth
24.99
6.97
52 Week Low
$50.08
$17.81
52 Week High
$77.16
$28.00

Technical Indicators

Market Signals
Indicator
RYAN
STVN
Relative Strength Index (RSI) 59.95 48.12
Support Level $55.54 $22.71
Resistance Level $57.84 $24.01
Average True Range (ATR) 1.40 1.24
MACD 0.14 0.12
Stochastic Oscillator 81.45 53.77

Price Performance

Historical Comparison
RYAN
STVN

About RYAN Ryan Specialty Holdings Inc.

Ryan Specialty Holdings Inc is a service provider of specialty products and solutions for insurance brokers, agents, and carriers. It provides distribution, underwriting, product development, administration, and risk management services by acting as a wholesale broker and a managing underwriter.

About STVN Stevanato Group S.p.A.

Stevanato Group SpA is a provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. It delivers an integrated, end-to-end portfolio of products, processes, and services that address customer needs across the entire drug life cycle including development, clinical, and commercial stages. It has two segments; Biopharmaceutical and Diagnostic Solutions which generates key revenue, includes all the products, processes and services developed and provided for the containment and delivery of pharmaceutical and biotechnology drugs and reagents, as well as the production of diagnostic consumables and its other segment is Engineering. Geographically, the company derives majority revenue from Europe, Middle East and Africa.

Share on Social Networks: